MX2016005510A - Profarmacos y moduladores de receptores nmda, sales y usos de estos. - Google Patents
Profarmacos y moduladores de receptores nmda, sales y usos de estos.Info
- Publication number
- MX2016005510A MX2016005510A MX2016005510A MX2016005510A MX2016005510A MX 2016005510 A MX2016005510 A MX 2016005510A MX 2016005510 A MX2016005510 A MX 2016005510A MX 2016005510 A MX2016005510 A MX 2016005510A MX 2016005510 A MX2016005510 A MX 2016005510A
- Authority
- MX
- Mexico
- Prior art keywords
- nmda receptor
- compounds
- prodrugs
- salts
- receptor modulators
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen los compuestos que tienen potencia mejorada en la modulación de la actividad del receptor NMDA. Se contemplan dichos compuestos para su uso en el tratamiento de enfermedades y trastornos, tales como trastornos de aprendizaje, actividades cognitivas y analgesia, particularmente en el alivio y/o reducción de dolor neuropático. También se describen las formulaciones disponibles oralmente y otras formas de administración farmacéuticamente aceptables de los compuestos, que incluyen formulaciones intravenosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896308P | 2013-10-28 | 2013-10-28 | |
| PCT/US2014/062367 WO2015065891A1 (en) | 2013-10-28 | 2014-10-27 | Nmda receptor modulators and prodrugs, salts, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005510A true MX2016005510A (es) | 2017-01-06 |
| MX378668B MX378668B (es) | 2025-03-10 |
Family
ID=53004986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005510A MX378668B (es) | 2013-10-28 | 2014-10-27 | Profarmacos y moduladores de receptores nmda, sales y usos de estos. |
| MX2021000029A MX2021000029A (es) | 2013-10-28 | 2016-04-27 | Profarmacos y moduladores de receptores nmda, sales y usos de estos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000029A MX2021000029A (es) | 2013-10-28 | 2016-04-27 | Profarmacos y moduladores de receptores nmda, sales y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9745342B2 (es) |
| EP (2) | EP3564256A1 (es) |
| JP (1) | JP6603668B2 (es) |
| KR (1) | KR20160077153A (es) |
| CN (2) | CN105764522A (es) |
| AU (2) | AU2014342624A1 (es) |
| BR (1) | BR112016009443A8 (es) |
| CA (1) | CA2928701A1 (es) |
| CL (2) | CL2016001001A1 (es) |
| IL (1) | IL245302B (es) |
| MX (2) | MX378668B (es) |
| RU (1) | RU2016119830A (es) |
| SA (1) | SA516371037B1 (es) |
| SG (2) | SG10201810496XA (es) |
| WO (1) | WO2015065891A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3598971T3 (pl) | 2013-01-22 | 2024-09-09 | Vistagen Therapeutics, Inc. | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny |
| CA3033564A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Acetyl-leucine for neurodegenerative diseases |
| CN116082461B (zh) * | 2022-10-14 | 2023-11-14 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090263858A1 (en) * | 2004-09-14 | 2009-10-22 | Shionogi & Co., Ltd. | Process for synthesis of mucin-type peptides and muc1-related glycopeptides |
| CA2686827C (en) * | 2006-12-14 | 2014-09-16 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| ES2398310T3 (es) * | 2007-02-23 | 2013-03-15 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
| CN102186883B (zh) * | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda受体调节剂和其用途 |
| JP2012503025A (ja) * | 2008-09-22 | 2012-02-02 | エルロン・セラピューティクス・インコーポレイテッド | 精製されたポリペプチド組成物を調製するための方法 |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| JP6035326B2 (ja) | 2011-04-27 | 2016-11-30 | ノースウェスタン ユニバーシティ | アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法 |
-
2014
- 2014-10-27 CN CN201480064349.XA patent/CN105764522A/zh active Pending
- 2014-10-27 EP EP19159957.0A patent/EP3564256A1/en not_active Withdrawn
- 2014-10-27 SG SG10201810496XA patent/SG10201810496XA/en unknown
- 2014-10-27 EP EP14858298.4A patent/EP3062810A4/en not_active Withdrawn
- 2014-10-27 RU RU2016119830A patent/RU2016119830A/ru unknown
- 2014-10-27 KR KR1020167013971A patent/KR20160077153A/ko not_active Ceased
- 2014-10-27 AU AU2014342624A patent/AU2014342624A1/en not_active Abandoned
- 2014-10-27 US US15/033,031 patent/US9745342B2/en not_active Expired - Fee Related
- 2014-10-27 CA CA2928701A patent/CA2928701A1/en not_active Abandoned
- 2014-10-27 WO PCT/US2014/062367 patent/WO2015065891A1/en not_active Ceased
- 2014-10-27 JP JP2016552196A patent/JP6603668B2/ja not_active Expired - Fee Related
- 2014-10-27 MX MX2016005510A patent/MX378668B/es unknown
- 2014-10-27 SG SG11201603376UA patent/SG11201603376UA/en unknown
- 2014-10-27 CN CN202010688442.5A patent/CN112321678A/zh active Pending
- 2014-10-27 BR BR112016009443A patent/BR112016009443A8/pt not_active IP Right Cessation
-
2016
- 2016-04-25 IL IL245302A patent/IL245302B/en active IP Right Grant
- 2016-04-27 CL CL2016001001A patent/CL2016001001A1/es unknown
- 2016-04-27 MX MX2021000029A patent/MX2021000029A/es unknown
- 2016-04-28 SA SA516371037A patent/SA516371037B1/ar unknown
-
2017
- 2017-07-24 US US15/658,107 patent/US10590167B2/en not_active Expired - Fee Related
-
2020
- 2020-02-17 AU AU2020201109A patent/AU2020201109A1/en not_active Abandoned
- 2020-08-31 CL CL2020002247A patent/CL2020002247A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201810496XA (en) | 2018-12-28 |
| US20180127466A1 (en) | 2018-05-10 |
| AU2020201109A1 (en) | 2020-03-05 |
| AU2014342624A1 (en) | 2016-06-02 |
| CL2020002247A1 (es) | 2021-02-05 |
| RU2016119830A3 (es) | 2018-07-02 |
| US9745342B2 (en) | 2017-08-29 |
| EP3062810A4 (en) | 2017-05-03 |
| MX2021000029A (es) | 2021-03-25 |
| IL245302A0 (en) | 2016-06-30 |
| RU2016119830A (ru) | 2017-12-04 |
| KR20160077153A (ko) | 2016-07-01 |
| JP6603668B2 (ja) | 2019-11-06 |
| CA2928701A1 (en) | 2015-05-07 |
| EP3062810A1 (en) | 2016-09-07 |
| MX378668B (es) | 2025-03-10 |
| WO2015065891A1 (en) | 2015-05-07 |
| CN112321678A (zh) | 2021-02-05 |
| US20160244485A1 (en) | 2016-08-25 |
| US10590167B2 (en) | 2020-03-17 |
| JP2016537413A (ja) | 2016-12-01 |
| CL2016001001A1 (es) | 2016-12-16 |
| CN105764522A (zh) | 2016-07-13 |
| BR112016009443A8 (pt) | 2020-03-24 |
| SA516371037B1 (ar) | 2018-05-16 |
| SG11201603376UA (en) | 2016-05-30 |
| IL245302B (en) | 2020-05-31 |
| EP3564256A1 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375286B (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| PE20151416A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
| PE20151438A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| CO2019000943A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| PE20151436A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| DOP2017000087A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
| MX2020008107A (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. | |
| MX2016005510A (es) | Profarmacos y moduladores de receptores nmda, sales y usos de estos. | |
| MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
| CO2018004803A2 (es) | Compuestos oxa-diazaspiro que tienen actividad contra el dolor | |
| ECSP17025904A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos |